10月27日，英科医疗涨5.01%，截至发稿，报42.13元/股，成交5.65亿元，换手率2.95%，总市值275.86 亿元。 资料显示，英科医疗科技股份有限公司位于山东省淄博市临淄区齐鲁化学工业园清田路18号,香港湾仔 皇后大道东248号阳光中心40楼，成立日期2009年7月20日，上市日期2017年7月21日，公司主营业务涉 及涵盖个人防护、康复护理、其他产品三大板块。主营业务收入构成为：个人防护类91.47%，康复护 理类4.75%，其他产品3.77%。 截至发稿，罗文杰累计任职时间12年192天，现任基金资产总规模1389.99亿元，任职期间最佳基金回报 149.38%， 任职期间最差基金回报-47.6%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 数据显示，南方基金旗下1只基金位居英科医疗十大流通股东。南方中证500ETF（510500）二季度增持 96.72万股，持有股数669.8万股，占流通股的比例为1.43%。根据测算，今日浮盈 ...

10月27日，英科医疗涨5.01%，截至发稿，报42.13元/股，成交5.66亿元，换手率2.96%，总市值275.86 亿元。 资料显示，英科医疗科技股份有限公司位于山东省淄博市临淄区齐鲁化学工业园清田路18号,香港湾仔 皇后大道东248号阳光中心40楼，成立日期2009年7月20日，上市日期2017年7月21日，公司主营业务涉 及涵盖个人防护、康复护理、其他产品三大板块。主营业务收入构成为：个人防护类91.47%，康复护 理类4.75%，其他产品3.77%。 从基金十大重仓股角度 数据显示，浙商证券资管旗下1只基金重仓英科医疗。浙商汇金量化臻选股票A（011824）二季度持有 股数4.02万股，占基金净值比例为0.75%，位居第二大重仓股。根据测算，今日浮盈赚取约8.08万元。 责任编辑：小浪快报 浙商汇金量化臻选股票A（011824）成立日期2021年7月1日，最新规模6380.8万。今年以来收益 27.54%，同类排名1932/4219；近一年收益32.66%，同类排名1391/3877；成立以来收益17.3%。 浙商汇金量化臻选股票A（011824）基金经理为陈顾君。 截至发稿，陈顾君累计任职时间5 ...

Group 1 - In October 17, 2023, Yingke Medical experienced a decline of 5.05%, with a stock price of 43.20 yuan per share, a trading volume of 1.434 billion yuan, a turnover rate of 6.69%, and a total market capitalization of 28.287 billion yuan [1] - Yingke Medical Technology Co., Ltd. is located in Zibo City, Shandong Province, and was established on July 20, 2009, with its listing date on July 21, 2017. The company's main business includes three segments: personal protection, rehabilitation care, and other products [1] - The revenue composition of Yingke Medical is as follows: personal protection accounts for 91.47%, rehabilitation care for 4.75%, and other products for 3.77% [1] Group 2 - From the perspective of the top ten holdings of funds, one fund under Zheshang Securities Asset Management has a significant position in Yingke Medical. The Zheshang Huijin Quantitative Selected Stock A (011824) held 40,200 shares in the second quarter, representing 0.75% of the fund's net value, making it the second-largest holding [2] - The estimated floating loss for the fund on the current day is approximately 92,500 yuan. The Zheshang Huijin Quantitative Selected Stock A (011824) was established on July 1, 2021, with a latest scale of 63.808 million yuan. Year-to-date, it has achieved a return of 28.41%, ranking 1771 out of 4218 in its category; over the past year, it has returned 38.96%, ranking 1351 out of 3865; and since inception, it has returned 18.1% [2] Group 3 - The fund manager of Zheshang Huijin Quantitative Selected Stock A (011824) is Chen Gujun, who has been in the position for 5 years and 272 days. The total asset size of the fund is 204 million yuan, with the best fund return during his tenure being 40.06% and the worst being -7.57% [3]

Core Insights - Inke Medical experienced a 5.05% increase in stock price, reaching 44.97 yuan per share, with a trading volume of 818 million yuan and a turnover rate of 4.08%, resulting in a total market capitalization of 29.446 billion yuan [1] Company Overview - Inke Medical Technology Co., Ltd. is located in Zibo City, Shandong Province, and was established on July 20, 2009, with its listing date on July 21, 2017 [1] - The company's main business segments include personal protection (91.47% of revenue), rehabilitation care (4.75%), and other products (3.77%) [1] Fund Holdings - Zhejiang Merchants Securities Asset Management has a fund that heavily invests in Inke Medical, specifically the Zhejiang Merchants Huijin Quantitative Selected Stock A (011824), which held 40,200 shares, accounting for 0.75% of the fund's net value, making it the second-largest holding [2] - The fund has generated a floating profit of approximately 86,800 yuan as of the report date [2] Fund Performance - The Zhejiang Merchants Huijin Quantitative Selected Stock A fund was established on July 1, 2021, with a current size of 63.808 million yuan [2] - Year-to-date, the fund has achieved a return of 29.32%, ranking 1753 out of 4218 in its category, while its one-year return stands at 39.78%, ranking 1330 out of 3864 [2]

Group 1 - The core point of the news is that Yingke Medical's stock price increased by 5.05% to 44.97 CNY per share, with a trading volume of 8.11 billion CNY and a turnover rate of 4.04%, resulting in a total market capitalization of 294.46 billion CNY [1] - Yingke Medical, established on July 20, 2009, and listed on July 21, 2017, operates in three main business segments: personal protection (91.47% of revenue), rehabilitation care (4.75%), and other products (3.77%) [1] Group 2 - Among the top ten circulating shareholders of Yingke Medical, E Fund's Chuangye ETF (159915) reduced its holdings by 272,900 shares in the second quarter, now holding 10.6244 million shares, which accounts for 2.26% of circulating shares [2] - The E Fund Chuangye ETF (159915) was established on September 20, 2011, with a latest scale of 85.537 billion CNY, achieving a year-to-date return of 43.03% and a one-year return of 46.72% [2] Group 3 - The fund managers of E Fund Chuangye ETF are Cheng Xi and Liu Shurong, with Cheng having a tenure of 9 years and 165 days and a total fund size of 195.312 billion CNY, while Liu has a tenure of 8 years and 93 days with a fund size of 112.299 billion CNY [3]

Group 1 - The core point of the news is that Yingke Medical's stock price increased by 5.23% to 38.62 CNY per share, with a trading volume of 391 million CNY and a turnover rate of 2.25%, resulting in a total market capitalization of 25.288 billion CNY [1] - Yingke Medical, established on July 20, 2009, and listed on July 21, 2017, operates in three main business segments: personal protection (91.47% of revenue), rehabilitation care (4.75%), and other products (3.77%) [1] Group 2 - Dachen Fund has a significant holding in Yingke Medical, with its Dachen Growth Mixed Fund (160926) increasing its stake by 120,000 shares in the second quarter, bringing the total to 848,900 shares, which accounts for 3.37% of the fund's net value [2] - The Dachen Growth Mixed Fund has a current size of 449 million CNY and has achieved a year-to-date return of 26.47%, ranking 4062 out of 8166 in its category [2] Group 3 - The fund manager of Dachen Growth Mixed Fund is Zou Jian, who has been in the position for 4 years and 259 days, managing a total asset size of 1.086 billion CNY [3] - During Zou Jian's tenure, the best fund return was 12.49%, while the worst return was -21.29% [3]

Group 1 - The core viewpoint of the news is that Yingke Medical has seen a significant increase in its stock price, rising by 5.33% to 38.76 CNY per share, with a trading volume of 444 million CNY and a turnover rate of 2.54%, resulting in a total market capitalization of 25.38 billion CNY [1] - Yingke Medical, established on July 20, 2009, and listed on July 21, 2017, operates in three main business segments: personal protection (91.47% of revenue), rehabilitation care (4.75%), and other products (3.77%) [1] - The company is located in Zibo City, Shandong Province, and has its Hong Kong office at 40/F, Sunshine Center, 248 Queen's Road East, Wanchai [1] Group 2 - From the perspective of fund holdings, a fund under Zheshang Securities Asset Management has a significant position in Yingke Medical, with Zheshang Huijin Quantitative Selected Stocks A (011824) holding 40,200 shares, accounting for 0.75% of the fund's net value, making it the second-largest holding [2] - The fund has achieved a year-to-date return of 27.29%, ranking 2094 out of 4220 in its category, and a one-year return of 58.4%, ranking 1473 out of 3824 [2] - The fund manager, Chen Gujun, has been in position for 5 years and 251 days, with the fund's total asset size at 204 million CNY and a best return of 35.77% during his tenure [3]

Core Viewpoint - In recent trading, Yingke Medical's stock price has shown significant growth, with a year-to-date increase of 49.08% and a market capitalization of 24.581 billion yuan [1] Group 1: Stock Performance - As of September 26, Yingke Medical's stock price rose by 2.01% to 37.54 yuan per share, with a trading volume of 171 million yuan and a turnover rate of 1.00% [1] - The stock has experienced a 5-day increase of 5.27%, a 20-day increase of 2.21%, and a 60-day increase of 46.64% [1] Group 2: Financial Performance - For the first half of 2025, Yingke Medical reported a revenue of 4.913 billion yuan, representing a year-on-year growth of 8.90%, and a net profit attributable to shareholders of 710 million yuan, up 21.02% year-on-year [2] Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders for Yingke Medical was 60,000, a decrease of 2.96% from the previous period, with an average of 7,825 circulating shares per person, an increase of 3.07% [2] - The company has distributed a total of 1.903 billion yuan in dividends since its A-share listing, with 245 million yuan distributed in the last three years [3] Group 4: Institutional Holdings - As of June 30, 2025, the second-largest circulating shareholder is Huabao Zhongzheng Medical ETF, holding 15.0151 million shares, an increase of 291,500 shares from the previous period [3] - Other notable institutional shareholders include E Fund Growth ETF and Southern CSI 500 ETF, with varying changes in their holdings [3]

Group 1 - The core point of the news is that Yingke Medical's stock price has dropped by 5.01% to 34.16 CNY per share, with a trading volume of 546 million CNY and a turnover rate of 3.38%, resulting in a total market capitalization of 22.368 billion CNY [1] - Yingke Medical, established on July 20, 2009, and listed on July 21, 2017, is located in Zibo City, Shandong Province, and operates in three main business segments: personal protection (90.31% of revenue), rehabilitation care (4.81%), and other products (4.89%) [1] Group 2 - From the perspective of major fund holdings, Dachen Fund has one fund heavily invested in Yingke Medical, specifically the Dachen Growth Enterprise Two-Year Open Mixed A Fund (160926), which increased its holdings by 120,000 shares in the second quarter, bringing the total to 848,900 shares, accounting for 3.37% of the fund's net value [2] - The Dachen Growth Enterprise Two-Year Open Mixed A Fund has a current scale of 449 million CNY and has achieved a year-to-date return of 22.17%, ranking 3332 out of 8180 in its category, with a one-year return of 39.93%, ranking 3389 out of 7978 [2]